GoAI
Get started
Vivos Therapeutics, Inc. logo

Vivos Therapeutics, Inc.

VVOS

NASDAQHealthcareMedical - Devices

Open in GoAI

Previous close

$0.297

+$0.0179 · +6.41%

Aug 21, 4:00 PM ET

VVOS company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

67

Undervalued

Momentum

17

Strong Down

Sentiment

59

Mixed

Risk resilience

4

Extreme Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was formerly known as Vivos BioTechnologies, Inc. and changed its name to Vivos Therapeutics, Inc. in March 2018. The company was founded in 2016 and is based in Littleton, Colorado.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
R. Kirk Huntsman
Listed since
Dec 11, 2020
Employees
268

Market position

Day range

Current $0.297

52-week range

Current $0.297

Open
$0.288
Previous close
$0.2791
Volume
104.19K
0.06× average
Average volume
1.82M
Average daily volume
Market cap
4.13M USD
Beta
6.09
Market reference 1
50-day average
$0.4155
-28.52% below average
200-day average
$1.2429
-76.10% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
32.33M USD
P/E (TTM)
-0.14×
P/B (TTM)
-1.38×
P/S (TTM)
0.2×
EV / EBITDA
-1.62×
Earnings yield
-101.79%
Free cash flow yield
-84.41%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
59.72%
Operating margin
-107.92%
Net margin
-122.42%
Return on equity
1424.83%
Return on assets
-84.41%
Return on invested capital
-123.14%

Financial health

Debt / equity
-3.18×
Current ratio
0.24×
Altman Z-score
-11.23
Piotroski F-score
3 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends98%5%-87%-179%Gross margin, FY2021: 74.65%Gross margin, FY2022: 62.52%Gross margin, FY2023: 59.93%Gross margin, FY2024: 60.00%Gross margin, FY2025: 60.44%Operating margin, FY2021: -115.32%Operating margin, FY2022: -156.21%Operating margin, FY2023: -125.32%Operating margin, FY2024: -74.32%Operating margin, FY2025: -114.05%Net margin, FY2021: -120.15%Net margin, FY2022: -148.81%Net margin, FY2023: -98.42%Net margin, FY2024: -74.09%Net margin, FY2025: -121.71%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 74.65%. Gross margin FY2022 62.52%. Gross margin FY2023 59.93%. Gross margin FY2024 60.00%. Gross margin FY2025 60.44%. Operating margin FY2021 -115.32%. Operating margin FY2022 -156.21%. Operating margin FY2023 -125.32%. Operating margin FY2024 -74.32%. Operating margin FY2025 -114.05%. Net margin FY2021 -120.15%. Net margin FY2022 -148.81%. Net margin FY2023 -98.42%. Net margin FY2024 -74.09%. Net margin FY2025 -121.71%.

Income trends

Revenue

17.44M USD+16.05%

Operating income

−19.89M USD-78.09%

Net income

−21.23M USD-90.64%
Income trends across reported periods21.69M USD4.7M USD−12.29M USD−29.28M USDRevenue, FY2021: 16.89M USDRevenue, FY2022: 16.02M USDRevenue, FY2023: 13.8M USDRevenue, FY2024: 15.03M USDRevenue, FY2025: 17.44M USDOperating income, FY2021: −19.47M USDOperating income, FY2022: −25.03M USDOperating income, FY2023: −17.3M USDOperating income, FY2024: −11.17M USDOperating income, FY2025: −19.89M USDNet income, FY2021: −20.29M USDNet income, FY2022: −23.85M USDNet income, FY2023: −13.58M USDNet income, FY2024: −11.14M USDNet income, FY2025: −21.23M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 16.89M USD. Revenue FY2022 16.02M USD. Revenue FY2023 13.8M USD. Revenue FY2024 15.03M USD. Revenue FY2025 17.44M USD. Operating income FY2021 −19.47M USD. Operating income FY2022 −25.03M USD. Operating income FY2023 −17.3M USD. Operating income FY2024 −11.17M USD. Operating income FY2025 −19.89M USD. Net income FY2021 −20.29M USD. Net income FY2022 −23.85M USD. Net income FY2023 −13.58M USD. Net income FY2024 −11.14M USD. Net income FY2025 −21.23M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue17.44M USD15.03M USD13.8M USD16.02M USD16.89M USD
Cost of goods sold6.9M USD6.01M USD5.53M USD6.01M USD4.28M USD
Gross profit10.54M USD9.02M USD8.27M USD10.02M USD12.6M USD
Selling, general, and administrative29.13M USD19.61M USD24.95M USD34.38M USD31.34M USD
Operating expenses30.44M USD20.19M USD25.57M USD35.05M USD32.08M USD
Interest income———89K USD117K USD
Interest expense————14K USD
Depreciation and amortization1.31M USD581K USD621K USD669K USD733K USD
Operating income−19.89M USD−11.17M USD−17.3M USD−25.03M USD−19.47M USD
Net income−21.23M USD−11.14M USD−13.58M USD−23.85M USD−20.29M USD

Company facts updated Aug 24, 2026.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$2.13

617.17% upside
Past 12 months12-month forecast

Price history unavailable

High $2.50Average $2.13Low $1.75

Rating distribution

5 ratings
Strong buy00%
Buy5100%
Hold00%
Sell00%
Strong sell00%

VVOS news

globenewswire.com

Vivos Therapeutics Opens New Sleep Testing and Treatment Facility in Nevada to Meet Rapidly Growing Patient Demand for Sleep Apnea Testing and Treatment

Vivos Therapeutics Opens New Sleep Testing and Treatment Facility in Nevada to Meet Rapidly Growing Patient Demand for Sleep Apnea Testing and Treatment

Read source
zacks.com

Vivos Therapeutics, Inc. (VVOS) Reports Q2 Loss, Lags Revenue Estimates

Vivos Therapeutics, Inc. (VVOS) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to a loss of $0.55 per share a year ago.

Read source
seekingalpha.com

Vivos Therapeutics, Inc. (VVOS) Q2 2026 Earnings Call Transcript

Vivos Therapeutics, Inc. (VVOS) Q2 2026 Earnings Call Transcript

Read source
globenewswire.com

Vivos Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Update

Quarter highlighted by steadily increasing patient demand for Vivos' differentiated array of highly effective OSA treatments Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., Aug. 14, 2026 (GLOBE…

Read source
globenewswire.com

Vivos Therapeutics Schedules Release of Second Quarter 2026 Financial Results and Conference Call

LITTLETON, Colo., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a leading medical device and healthcare services company focused on developing and commercializing…

Read source
globenewswire.com

Vivos Therapeutics Expands Greenway Health Partnership to Deploy AI-Enabled Platform Across All Clinical and Revenue Operations

Greenway analysis estimates AI-enabled automation in Nevada alone could create up to $9.0 million in potential annual value, including approximately $8.0 million from increased patient capacity and $1.0 million from…

Read source

Corporate actions

Corporate action history

Stock split

Effective Oct 27, 2023

1:25

VVOS peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding VVOS

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
24.86K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%

Continue in GoAI

Research VVOS

research.disclaimer